Business
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML (MB-106) and opens the Phase 2 portion for recruitment \n– Announces a preliminary CR/CRi rate of 33% (n=6) in the Phase 1B portion of its MB-106 clinical trial\n– Reports preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of soft tissue sarcoma metastasized to the lungs with 73% (n=26) of the subjects exhibiting stable disease after two cycles of treatment\n– Multiple expected milestones and interim data readouts expected in 2023 \nHOUSTON, Aug. 10, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today provided an update on recent activity and expected near term milestones across its clinical development pipeline.\n\n \n \n \n \n \n \n\n \n\"We continue to make solid progress across our development pipeline and ongoing clinical trials and are extremely encouraged by our Annamycin AML and STS programs. Our team remains focused on executing our clinical development and driving recruitment forward in our three ongoing Phase 1b/2 clinical trials to meet the milestones ahead for each program. With the data Annamycin continues to generate, we are excited about the potential for further positive data readouts throughout the remainder of 2023,\" commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. \"Additionally, we continue to have encouraging discussions for externally funded, investigator-initiated trials and believe we are well positioned to bring those discussions to fruition in 2023. I believe Moleculin is poised to build on its momentum and maximize value for both patients and shareholders.\"\nOngoing Clinical Trial Updates \nNext Generation Anthracycline – Annamycin\nAnnamycin is the Company's next-generation anthracycline that has been designed to be non-cardiotoxic (unlike currently prescribed anthracyclines) and has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin (a commonly prescribed anthracycline), as well as demonstrating the ability to avoid the multidrug resistance mech...